|

Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer

RECRUITINGPhase 3Sponsored by University of Utah
Actively Recruiting
PhasePhase 3
SponsorUniversity of Utah
Started2018-02-02
Est. completion2026-11-30
Eligibility
Healthy vol.Accepted
Locations5 sites

Summary

This randomized phase III trial studies short course vaginal cuff brachytherapy to see how well it works compared with standard of care vaginal cuff brachytherapy in treating participants with stage I-II endometrial cancer. Short course vaginal cuff brachytherapy, also known as internal radiation therapy, uses (over a shorter period) radioactive material placed directly into or near a tumor in the upper portion of the vagina to kill tumor cells. After completion of cohort 1 (108 participants), the protocol was expended to add a second cohort of 80 additional participants, and re-opened study recruitment.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Histologically confirmed endometrial carcinoma: endometrioid type, serous, and clear cell, to include tumors originating in the cervix, but are primarily located in the uterus, and for whom vaginal cuff brachytherapy is indicated. Carcinosarcoma and other sarcomas are permitted; Federation of Gynecology and Obstetrics (FIGO) stage I and stage II, with one of the following combinations of stage and grade:

  * Stage IA, grade 1 with LVSI, 2, 3
  * Stage IB, grades 1-3
  * Stage II, grades 1-3
  * Stage IIIA, grades 1-3, not receiving EBRT as part of adjuvant therapy.
* Participants post-hysterectomy and free from residual disease.
* World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG)-performance status 0-2.
* Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.
* Life expectancy of \>2 years.

Exclusion Criteria:

* Stages of endometrial carcinoma other than described.
* Previous pelvic radiotherapy.
* Concurrent malignancy requiring non-protocol anti-cancer treatment other than surgery.

Conditions10

CancerEndometrial Clear Cell AdenocarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Serous AdenocarcinomaStage I Uterine Corpus CancerStage IA Uterine Corpus CancerStage IB Uterine Corpus CancerStage II Uterine Corpus CancerUterine Corpus CarcinosarcomaUterine Corpus Sarcoma

Locations5 sites

California

1 site
Stanford Cancer Center
Palo Alto, California, 94304

Illinois

1 site
Loyola University Medical Center
Maywood, Illinois, 60153
Carly Quick, RN708-327-3255Carly.quick@luhs.org

Texas

1 site
MD Anderson
Houston, Texas, 77030
Mathew G Geena713-792-4594geenag@mdanderson.org

Utah

2 sites
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
Rachel Kingsford801-585-0115rachel.kingsford@hci.utah.edu
Intermountain Medical Center / LDS Hospital
Salt Lake City, Utah, 84143

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.